Bioventus (NASDAQ:BVS) Upgraded by Wall Street Zen to "Strong-Buy" Rating

Key Points

• Bioventus has been upgraded to a "strong-buy" rating by analysts at Wall Street Zen, indicating increased confidence in the company's stock.
• The company's stock currently has a market capitalization of $568.41 million and a price-to-earnings ratio of -14.42.
• Despite recently posting earnings per share (EPS) of $0.21, Bioventus missed analysts' expectations by $0.01, reflecting some challenges in their financial performance.

Bioventus (NASDAQ:BVS - Get Free Report) was upgraded by analysts at Wall Street Zen from a "buy" rating to a "strong-buy" rating in a note issued to investors on Saturday.

Bioventus Stock Performance

Shares of NASDAQ BVS opened at $6.92 on Friday. The stock has a market capitalization of $568.41 million, a price-to-earnings ratio of -14.42 and a beta of 0.83. The company has a debt-to-equity ratio of 1.48, a quick ratio of 0.89 and a current ratio of 1.48. Bioventus has a twelve month low of $5.81 and a twelve month high of $14.38.

Bioventus (NASDAQ:BVS - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The company reported $0.21 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.22 by ($0.01). Bioventus had a positive return on equity of 23.04% and a negative net margin of 0.03%.

About Bioventus

Bioventus Inc a medical device company, focuses on developing and commercializing clinically treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's portfolio of products includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.